Agoracom Blog

Lexaria Intends to Complete a $900,000 Financing

Posted by AGORACOM-JC at 9:12 AM on Friday, August 8th, 2014

Kelowna, British Columbia–(August 8, 2014) – Lexaria Corp. (OTCQB: LXRP) (CSE: LXX) (the “Company” or “Lexaria”) reports its intention to complete a non-brokered private placement financing, consisting of 6,000,000 Equity Units at US $0.15 per unit, to raise gross proceeds of up to US $900,000 (the “Private Placement”).

Each equity unit will consist of one common share of the Company and one non-transferable share purchase warrant, each warrant entitling the holder to purchase one additional common share of the Company for a period of eighteen months from the date of issuance, at a purchase price of US$0.25. The Company may accelerate the expiry date of the warrants if the stock price trades above CAD$0.60 for 20 consecutive days at any time after 6 months and one day has elapsed.

Lexaria may pay broker commissions of up to 6.0% in cash and 6% in broker warrants in connection with the Private Placement. Each broker’s warrant will be exercisable into one single common share (a “Warrant Share”) at a price of US$0.25 per Warrant Share for a period of eighteen (18) months following closing of the Offering. Certain directors, officers and insiders of the Company may participate in the Private Placement.

The Company is canceling its earlier announced intention to complete a non-brokered private placement financing, consisting of 17,000,000 Equity Units at US $0.20 per unit, to raise gross proceeds of up to US $3,400,000 (the “Private Placement”) due to market conditions and the increased dilution the larger proposed financing would have caused.

The securities issued will be subject to a hold period in Canada of four months and one day, or for any resales possible into the USA under Rule 144, six months and one day. Proceeds from the equity units will be used for corporate development in the Medical Marijuana business, G&A and general working capital. The Private Placement will be subject to normal regulatory approvals.

The securities referred to herein will not be or have not been registered under the United States Securities Act of 1933, as amended, and may not be offered or sold in the United States absent registration or an applicable exemption from registration requirements.

About Lexaria

Lexaria’s shares are quoted in the USA with symbol LXRP and in Canada with symbol LXX. The company searches for projects that could provide potential above-market returns. To learn more about Lexaria Corp. visit www.lexariaenergy.com.

FOR FURTHER INFORMATION PLEASE CONTACT:

Lexaria Corp.
Chris Bunka, CEO: (250) 765-6424
Clark Kent, Media Manager: (647) 519-2646

FORWARD-LOOKING STATEMENTS

This release includes forward-looking statements. Statements which are not historical facts are forward-looking statements. The Company makes forward-looking public statements concerning its expected future financial position, results of operations, cash flows, financing plans, business strategy, products and services, competitive positions, growth opportunities, plans and objectives of management for future operations, including statements that include words such as “anticipate,” “if,” “believe,” “plan,” “estimate,” “expect,” “intend,” “may,” “could,” “should,” “will,” and other similar expressions are forward-looking statements. Such forward-looking statements are estimates reflecting the Company’s best judgment based upon current information and involve a number of risks and uncertainties, and there can be no assurance that other factors will not affect the accuracy of such forward-looking statements. It is impossible to identify all such factors but they include and are not limited to the existence of underground deposits of commercial quantities of oil and gas; cessation or delays in exploration because of mechanical, weather, operating, financial or other problems; capital expenditures that are higher than anticipated; or exploration opportunities being fewer than currently anticipated. There can be no assurance that road or site conditions will be favorable for field work; no assurance that well treatments or workovers will have any effect on oil or gas production; no assurance that oil field interconnections will have any measurable impact on oil or gas production or on field operations, and no assurance that any expected new well(s) will be drilled or have any impact on the Company. There can be no assurance that expected oil and gas production will actually materialize; and thus no assurance that expected revenue will actually occur. There is no assurance the Company will have sufficient funds to drill additional wells, or to complete acquisitions or other business transactions. Such forward looking statements also include estimated cash flows, revenue and current and/or future rates of production of oil and natural gas, which can and will fluctuate for a variety of reasons; oil and gas reserve quantities produced by third parties; and intentions to participate in future exploration drilling. Adverse weather conditions including but not limited to surface flooding can delay operations, impact production, and cause reductions in revenue. The Company may not have sufficient expertise to thoroughly exploit its oil and gas properties. The Company may not have sufficient funding to thoroughly explore, drill or develop its properties. Access to capital, or lack thereof, is a major risk and there is no assurance that the Company will be able to raise required working capital. Current oil and gas production rates may not be sustainable and targeted production rates may not occur. Factors which could cause actual results to differ materially from those estimated by the Company include, but are not limited to, government regulation, managing and maintaining growth, the effect of adverse publicity, litigation, competition and other factors which may be identified from time to time in the Company’s public announcements and filings. There is no assurance that the medical marijuana business will provide any benefit to Lexaria and no assurance that the proposed financing of up to $900,000 will be successful.

The CNSX has not reviewed and does not accept responsibility for the adequacy or accuracy of this release.

Start your small cap medical marijuana research in the AGORACOM Small Cap 
Medical Marijuana Stocks Gateway: 
http://agoracom.com/portal/Small%20Cap%20Medical%20Marijuana%20Stocks

Tags: , , ,

Comments are closed.